PHIO PHARMACEUTICALS CORP. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
PHIO PHARMACEUTICALS CORP. (PHIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.11% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-05
- PHIO PHARMACEUTICALS CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.11%.
- PHIO PHARMACEUTICALS CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.80%.
- PHIO PHARMACEUTICALS CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.50%.
- PHIO PHARMACEUTICALS CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.80%, a 500.00% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.11% 10-K · filed 2026-03-05 | |
| 2024-12-31 | -0.80% 10-K · filed 2026-03-05 | |
| 2023-12-31 | -0.50% 10-K · filed 2025-03-31 | |
| 2022-12-31 | -0.80% 10-K · filed 2024-04-01 | |
| 2021-12-31 | 0.20% 10-K · filed 2023-03-22 | |
| 2020-12-31 | -0.50% 10-K · filed 2022-03-22 | |
| 2019-12-31 | -0.20% 10-K · filed 2021-03-25 | |
| 2018-12-31 | -1.20% 10-K · filed 2020-03-26 | |
| 2017-12-31 | 0.50% 10-K · filed 2019-03-27 | |
| 2016-12-31 | 1.70% 10-K · filed 2018-03-26 | -1.70% 10-K · filed 2017-03-30 |
| 2015-12-31 | -1.90% 10-K · filed 2017-03-30 | 1.90% 10-K · filed 2016-03-30 |
| 2014-12-31 | 2.10% 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |